Communiqués Vertex Pharmaceuticals Incorporated

Actions

VRTX

US92532F1003

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/07/2026			Varia. 5j.	Varia. 1 janv.
498,01 ^USD	+0,26 %		+4,80 %	+9,85 %

10:10	Vertex Pharmaceuticals reçoit l'approbation de la FDA pour l'extension de l'indication de Casgevy aux patients dès l'âge de 2 ans atteints de drépanocytose ou de bêta-thalassémie dépendante des transfusions	CI
09:55	Vertex Pharmaceuticals : la FDA autorise l'extension de l'utilisation du Casgevy aux jeunes enfants atteints de troubles sanguins	MT

Communiqués

01:59	Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia	BU
11/06	Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions	BU
05/06	Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference	BU
03/06	Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10	BU
01/06	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	BU
11/05	Vertex to Participate in Upcoming May Investor Conferences	BU
07/05	Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany	AQ
06/05	Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany	BU
06/05	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q)	PU
04/05	Vertex Pharmaceuticals Incorporated : Q1 26 VRTX Earnings Presentation	PU
04/05	Vertex: Q1 Earnings Snapshot	AQ
04/05	Vertex Reports First Quarter 2026 Financial Results	BU
16/04	Vertex Pharmaceuticals Incorporated : 2025 Corporate Responsibility Report	PU
16/04	Vertex Pharmaceuticals Incorporated : 2025 Data Summary	PU
06/04	Vertex to Announce First Quarter 2026 Financial Results on May 4th	BU
01/04	Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States	BU
25/03	Vertex Pharmaceuticals Incorporated : 2025 (2025 Political Engagement Principles)	PU
13/03	AM Best Affirms Credit Ratings of Torreyana Insurance Company, Inc	AQ
09/03	Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy	BU
05/03	Vertex to Participate in Upcoming March Investor Conferences	BU
05/03	Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures	BU
17/02	Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3	BU
12/02	Vertex Pharmaceuticals Incorporated : Q4 2025 Presentation (6759ed5a 3de5 4ea9 81b2 ba99abfb333f)	PU
12/02	Vertex Reports Fourth Quarter and Full Year 2025 Financial Results	BU
20/01	Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th	BU